Vast arrays of structural forms are accessible to simple amyloid peptides and environmental conditions can direct assembly into single phases. These insights are now being applied to the aggregation of the Aβ peptide of Alzheimer's disease (AD) and the identification of causative phases. We extend use of the imaging agent Pittsburgh compound B (PiB) to discriminate among Aβ phases and begin to define conditions of relevance to the disease state. And we specifically highlight the development of methods for defining the structures of these more complex phases.
Introduction
Protein misfolding events are now implicated in at least 50 disease states, and among these, the neurodegenerative maladies represent a personal and societal tragedy of immense and growing proportions. Despite progress in identifying these diseases, recent therapeutic strategies directed at controlling the production and aggregation of pathogenic proteins have all been disappointing. 1 However, several key observations common to these diseases have emerged, including (i) the demonstration of a remarkable diversity of assembled forms accessible to a given protein sequence, (ii) the documentation of individual forms that propagate through a conformational Darwinian selection process to give distinct strains, and (iii) the definition of nucleation and propagation events that are strongly influenced by the assembly environment. These proteinaceous aggregates then arise in a context dependent manner, and the selected forms, or strains, spread by an endogenous prion-like process of conformational templating. The genetic and environmental risk factors associated with Alzheimer's disease (AD), probably the best known of these misfolding disorders, are largely associated with the metabolism, trafficking or aggregation of the 39-42 residue Aβ peptide. [42] [43] [44] However, some individuals with substantial Aβ deposition in the brain show no clinical signs of AD. 45, 46 Similarly, nonhuman primates, which accumulate copious deposits of Aβ with age, 47 also fail to develop the key features of AD including neurofibrillary tangles, neuronal loss, and dementia. 48 Resolution of this apparent paradox may be rooted in proteins that aggregate and propagate into structurally and functionally distinct strains with only certain strains being critical for disease. 8, 47, [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] To explore the hypothesis that specific strains underlie the observed disease states, we have been developing methods to distinguish pathogenic from benign Aβ strains. Defining the architectural features of these strains 50 has required the development of new methods that address the structural challenges associated with these misfolded assemblies. Recognizing that defining the replicating environment will be critical for propagation of any selected assembly, we have further developed methods to propagate and characterize assemblies from more heterogeneous environments. Here we combine those methods in a coherent framework for defining the structural basis for AD and possibly other disease states.
Results and Discussion
Identifying AD-relevant strains AD is diagnosed postmortem by the identification of two characteristic lesions in the brain: senile plaques and neurofibrillary tangles. 43, 62 Senile plaques contain extracellular deposits of micron long, unbranched fibers composed of Aβ, a ~4kDa cleavage product of the βamyloid precursor protein (APP). 44, 63, 64 Neurofibrillary tangles are intracellular polymers of the microtubule-associated tau protein. 65 Current evidence indicates that the tauopathy of AD is downstream of Aβ aggregation, 42, 43 and that the pathogenic process begins in the brain many years before the onset of dementia. 66 Furthermore, the type and distribution of Aβ deposits in the brain can vary considerably, both within and among AD brains, possibly reflecting different initiating events. 50 Hence, understanding the misfolding, aggregation, and propagation of Aβ phases will be an important step toward elucidating both the critical early stages of AD as well as the antecedents of degenerative changes in end-stage disease.
Recently, we found that high-affinity binding sites for the Aβ-imaging agent Pittsburgh compound B (PiB) ( Fig 1A) are much more abundant on Aβ aggregates from human AD brains than from aged nonhuman primate brains 47 , which deposit large amounts of Aβ in brain, but do not develop AD. 48, 67 In vitro, our studies and others show that the peptide conformation of Aβ aggregates is strongly determined by the conditions of aggregation, 52, 55, 56, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] and thus PiB may serve as a critical probe for an AD-specific strain of Aβ and help define the conditions under which strains develop.
To test this assertion in vitro, we incubated 1mg/mL Aβ peptides in 10mM phosphate buffer (pH 7.4) under conditions of constant agitation 52, 55 (Ag) and generated shorter and more twisted fibers compared to quiescent 51, 77, 78 (Q) incubation ( Fig 1B,C) . Both fibers are composed of parallel in-register β-sheets, with the agitated fibers having a triangular crosssection with 3 peptides per unit-length 55 , defined by the H-bonding repeat within the fiber, in contrast the quiescent fibers have two peptides per unit-length. 81, 82 Aβ(1-40) Ag vs. Q assemblies also show different affinity for [ 3 H]PiB ( Fig 1D) ; Ag fibers have almost three times as many binding sites as the Q fibers. A similar trend is observed for Aβ Characterization of assemblies identified from in vivo PiB binding now provides a unique opportunity to define the structural features of β-amyloid strains that are specific for AD. [ 19 F]PiB binds with similar affinity in vivo, [83] [84] [85] opening the possibility to greatly increase sensitivity for specific 13 C/ 15 N -19 F distances to be defined with 13 C/ 15 N-enriched Aβ peptide through 13 C/ 15 N{ 19 F}REDOR (Rotational-Echo Double-Resonance) 86, 87 solid-state NMR measurements. To optimize these experiments for eventual characterization of in vivo assemblies, we have developed the 13 C -19 F distance measurement within amyloid assemblies of the central nucleating core of the Aβ peptide, [88] [89] [90] Aβ (16) (17) (18) (19) (20) (21) (22) , Ac- 16 KLVFFA 22 E-NH 2 , using trifluoroacetic acid (TFA) association. Aβ (16) (17) (18) (19) (20) (21) (22) assembled phases are now the most thoroughly characterized amyloid structure (see ref 68 and references therein). 13 C{ 15 N}REDOR 86 solid-state NMR measurements of N-acetyl-[1-13 C]LV18 [ 15 N]A21 Aβ (16) (17) (18) (19) (20) (21) (22) peptides assembled at low pH resolves V18 13 CO dipole-dipole coupling to two backbone A21 amide 15 N's, one from the H-bonded residue (4.2 Å) and one from the non-H-bonded residue (5.4 Å) with an angle of 160° between the two 13 C-15 N internuclear vectors. 75 These constraints place all of the peptides in antiparallel, out-of-register β-sheets. Small-angle X-ray (SAXS) scattering of the N-acetyl Aβ (16) (17) (18) (19) (20) (21) (22) peptide assemblies fit to a hollow tube form factor with a 52 nm diameter and a 4.3 nm wall thickness. 91 The ~4 nm wall thickness was confirmed by TEM of crosssectioned Aβ (16) (17) (18) (19) (20) (21) (22) assemblies embedded in epoxy resin. 92 Given that the length of an extended seven-residue β-strand peptide is ~2.2 nm, one structural model has the tube wall defined by two peptides stacked end-to-end. If this arrangement was a peptide bilayer, the anti-parallel β-sheet registry would place the positively charged lysine side chain on both faces of each peptide leaflet, resulting in the burial of significant positive charge density at the leaflet interface ( Fig 2) . To determine whether TFA anions were involved in passivating this heavily charged interface, 13 C{ 19 F}REDOR methods were developed and used to establish that 13 C-enriched carbonyl carbons of the acetyl capping group at the N-terminus of N-acetyl Aβ (16) (17) (18) (19) (20) (21) (22) peptide, [1-13 C]acetyl Aβ (16) (17) (18) (19) (20) (21) (22) , were all within ~ 5 Å of an 19 F. 92 Most importantly, when the peptide nanotubes were washed with sulfate, the 13 C{ 19 F}REDOR dephasing data plateaued at ~50%, demonstrating that only half of the acetyl groups are close to an 19 F. 92 This result was consistent with a peptide bilayer where half of the lysines are solventexposed and half are buried within the leaflet interface ( Fig 2) . These findings demonstrate the potential of using 13 C-19 F distance measurement with amyloid peptides to structurally localize small molecules such as TFA within the amyloid assembly. The high sensitivity offered by 13 C dephasing by 19 F now opens the possibility of defining the binding site of [ 19 F]PiB on complex amyloid assemblies.
Context Dependence of Assembly
As suggested above, Aβ aggregate strains are strongly dependent on the conditions of assembly in vitro, 52, 55, 56, [68] [69] [70] [71] [72] [73] [74] [75] [76] but little information exists on the nature of the assemblies that form in vivo. Since the Aβ peptide associated with Alzheimer's disease is generated by proteolytic secretase cleavage within the transmembrane region of APP, 93 the initial steps of assembly may well occur within the neuronal plasma membrane. Indeed, immunohistochemical analysis Aβ bound to ganglioside in intraneuronal organelles 94 and Aβ assembly in the presence of model lipids [95] [96] [97] [98] [99] [100] [101] [102] has been used to mimic assembly in vivo. We designed a simple initial test of the effect of this environment on Aβ assembly by assembling Aβ in the presence of brain lipid extracts. TEM microscopy identified fibers and vesicles ( Fig 3A) . While characterization by IR and CD in these crude samples is challenging, β-sheet peptide conformation and registry can be specifically interrogated by measuring 13 C-15 N and 13 C-13 C backbone distances with solid-state NMR. [1-13 C]L34 [ 15 N]V36 Aβ(1-42) peptides were synthesized via solid-phase peptide chemistry and purified with reverse-phase HPLC to >99% purity. The Leu34 13 CO chemical shift resonance at 172.8 ppm ( Fig 3B) is consistent with protein β-strand chemical shifts. 103, 104 The i to i+2 intramolecular 13 C -15 N distance measured with 13 C{ 15 N}REDOR 86 uniquely defines a 13 C -15 N distance 105 of 4.1 Å, providing the initial assignment as parallel β-sheet Aβ(1-42) peptide assemblies. Aβ assembled in vitro has parallel in-register βsheets, [106] [107] [108] and this registry would place the Val34 carbonyl carbons 4.7Å apart. That no 13 C-13 C dipolar coupling between [1-13 C]Val34 carbons was observed in 13 C Double Quantum Filtered DRAWS 109, 110 solid-state NMR experiments (data not shown) suggests that, in the presence of lipid extracts, Aβ(1-42) assembles as a different phase.
To develop the necessary methods for characterizing any mixed molecular assemblies forming in the presence of brain lipids, a series of simple peptide/lipid chimeras were prepared with Aβ (16) (17) (18) (19) (20) (21) (22) N-acylated with fatty acid chains containing from 2 (N-acetyl) to 16 (N-palmitoyl) carbon atoms. 111 Remarkably, all of these chimeric peptides assembled and displayed the characteristic H-bonded β-sheet reflection at 4.7 Å by X-ray diffraction (XRD). 111 The laminate XRD d-spacing systematically increased as the chain length increased from 9.8 Å for C 2 to 13.5 Å for C 16 , with the two longest chains C 14 (Nmyristoyl) and C 16 giving fibers with two laminate reflections consistent with assemblies that had distinctly different β-sheet stacking distances. C 11 (N-undecanoyl) to C 13 (Ntridecanoyl) assembled as tubes morphologically identical to those formed by the shorter chain (C 2 -C 4 ) chimeric peptides. This similarity between the morphology of the two distinctly different peptide amphiphiles (N-acetyl (C 2 )-and N-lauroyl (C 12 )-Aβ (16-22 111 The peptide nanotube architectures were intriguingly similar; 111 both tubes had a wall thickness of ~4 nm as measured by AFM. Isotope-edited IR of [1-13 C]F19 N-acetyl and N-lauroyl Aβ (16) (17) (18) (19) (20) (21) (22) had identical 12 C and 13 C band splittings, indicating that both peptides form anti-parallel out-of-register β-sheets. Negatively charged 5nm Au colloidal nanoparticles bound to the surfaces of both assemblies with similar density and distribution, indicating that the terminal lysine side chain amines were protonated and exposed on the tube surface. 13 C{ 19 F} REDOR measurements of N- [1-13 C] acetyl and N-[1-13 C]lauroyl Aβ (16) (17) (18) (19) (20) (21) (22) peptides assembled in the presence of TFA and slowly bundled in the presence of sulfate or NADH, respectively, to remove the solvent-exposed TFA ions had similar REDOR dephasing plateaus, consistent with TFA anions buried within a peptide bilayer. 111 Initial molecular modeling of the N-lauroyl peptides arranged into a single anti-parallel outof-register β-sheet suggested that the lauroyl chain was bent over the peptide side chains. To localize the alkyl chain, distances from both ends of the lauroyl chain with 13 C enrichment of either the lauroyl methyl or carbonyl carbon were measured to the peptide backbone enriched with 15 N. 13 C{ 15 N}REDOR measurements of N-[1-13 C]lauroyl [ 15 N]L17 Aβ (16) (17) (18) (19) (20) (21) (22) peptides assembled into nanotubes fit to a 13 C-15 N distance of 3.7 Å indicating that, at the attachment point to the peptide, all of the lauroyl chains were bent as shown in Fig. 4A . Further, 13 C{ 15 N}REDOR measurements from the terminal methyl of the lauroyl chain to [ 15 N]L17 and [ 15 N]V18 ( Fig 4A) placed the methyl group closer to V18 than L17, and molecular modeling placed the end of the chain close to the middle of the peptide with the lauroyl chain snorkeling between two stacked anti-parallel out-of-register β-sheets. The commensurate increase in the distance between the β-sheets as observed in the XRD pattern, from 9.8Å to 11.5Å in this case, can now be used as a diagnostic signature for the incorporation of small molecules between the peptide bilayer leaflets and within the β-sheet laminate (Fig 4B & C) . This demonstrated structural plasticity of the cross-β architecture greatly expands the range of structures available in the cellular milieu where amyloid proteins assemble, and provides the methods necessary to define their structures.
Conclusion
In AD, the nucleation and aggregation of Aβ is an early and obligatory pathogenic event 1, [42] [43] [44] 62 that begins decades before symptoms appear. 66, 112 This timing, together with the context-dependent nature of assembly within neuronal tissues, 50 conspires to present one of the most daunting structural problems facing peptide science. Here we have demonstrated the development of methods for defining small molecule binding to complex amyloid arrays that exploit the greater sensitivity of the 13 C{ 19 F}REDOR experiments. These methods can now be directly applied to the differential binding of the Aβ-imaging agent PiB to Aβ aggregates from human AD brains. 47 Structural characterization will, however, require the preparation of sufficient amounts of the peptide assemblies for characterization. Maybe not surprisingly, our initial data suggest that Aβ(1-42) assemblies have different β-sheet registries in the presence of lipid brain extract. The full characterization of peptide/lipid chimera assemblies has identified unique areas of plasticity within the β-sheet laminates, and while this discovery does not directly explain the apparent registry shift in Aβ , it does provide perspective for how assembling within the complex milieu of brain tissues may impact the final structure. This sets the stage for the structural interrogation of amyloid strains similar to in vivo assemblies and the definition of their ultimate relationship to disease. Such methods may finally provide a route forward for the elucidation of the critical features that underlie AD and possibly other amyloid assemblies in a growing class of devastating diseases.
Methods

Peptide Synthesis and Purification
Peptides were synthesized using a Liberty CEM Microwave Automated Peptide Synthesizer (NC, USA) and a FMOC-L-Val-PEG-PS or FMOC-L-Ala-PEG-PS Resin (AnaSpec, CA, USA) for Aβ and Aβ(1-42) ( 1 DAEF 5 RHDSG 10 YEVHH 15 QKLVF 20 FAEDV 25 GSNKG 30 AIIGL 35 MVGGV 40 VIA) synthesis ,respectively, to give the free acid carboxy terminus upon cleavage from resin. FMOC-PEG-PS Resin was swollen using dimethylformamide for 15 minutes. Microwaveassisted FMOC deprotection was completed using 20% piperdine and 0.1M N-Hydroxybenzotriazole (HOBt) in dimethylformamide at 45-55°C for 180 sec, followed by 3X dimethylformamide flushes. Each FMOC-amino acid coupling step was performed using 0.1M FMOC protected amino acid, and activated with 0.1 M 2-(1H-Benzotriazole-1yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), and 0.2M N,N-Diisopropylethylamine (DIEA) in DMF. Coupling temperatures using microwave activation were maintained between 75 and 82°C for 300 sec except for histidine and arginine residues. Histidine was double-coupled for 600 sec at 50°C and arginine was coupled at room temp for 900 sec and 300 sec between 75 and 82°C. After each coupling step, resin was rinsed with three aliquots of dimethylformamide. Isotope-enriched peptides were synthesized by the Peptide Technology Facility of the Bio21 Molecular Science and Biotechnology Institute peptide synthesis facility (Melbourne, Australia).
Resin was filtered and washed with dichloromethane and allowed to air dry. Peptides were cleaved from the resin using trifluoroacetic acid/thioanisole/1,2-ethanedithiol/anisole (90:5:3 2, v/v/v/v) at room temperature for 3 hrs. The cleaved peptide-TFA solution was filtered, and precipitated by drop-wise addition to cold (−20°C) diethyl ether. Precipitated product was centrifuged at 3000 rpm for 10 min, and the pellet was further washed 3 times with cold diethyl ether. Dried peptides were dissolved in minimal volume of 40% acetonitrile + 0.1% trifluoroacetic acid and 8M Guanidinium chloride (Aldrich) and purified by RP-HPLC using a C18-reverse phase column with an acetonitrile-water +0.1%TFA gradient. In each case, the peptide purity was evaluated by HPLC. Molecular weight was confirmed by electro spray ionization (ESI) mass spectrometry. Acetonitrile was removed with rotary evaporation and peptides were lyophilized to dryness.
Peptide Assembly
For microscopy, Aβ and Aβ(1-42) lyophilized powder, synthesized as described above, was dissolved in minimal hexafluoroisopropanol (HFIP, Aldrich, MO) in glass vials for 2hrs, then dried under a steady stream of argon gas overnight to form a clear film. Peptides were assembled in 10mM phosphate buffer, pH 7.4, with 0.02% Na azide in 15 or 50 mL Falcon tubes. Agitated samples were placed on an orbital shaker (BellCo Glass Inc., Vineland NJ) with the shaker table maintained at 40 revolutions per minute. Agitated and quiescent samples were assembled for at least two weeks. For PiB binding assays, HFIPtreated lyophilized A(1-40) and A(1-42) (purchased from Anaspec) were brought up to 5mM stock concentration with anhydrous DMSO. Peptides were brought up to 100µM in sterile 0.01M PBS in 1.5mL polypropylene tubes and samples were spun at 14,000g for 10min at room temperature. Clear supernatants were transferred to clean tubes and incubated at 37°C for 25 days at rest or shaking at 450 rpm on an orbital shaker.
[ 3 H]PiB binding
In a 96-well polypropylene plate, 10 or 20 µL of Aβ assemblies (diluted in 5% ethanol/PBS) were added to each of duplicate wells. 100 or 200 µL of 1 nM [ 3 H]PIB (SA = 82 Ci/mmol, custom synthesis, GE Healthcare, UK) diluted in 5% ethanol/PBS were quickly added to each well. Samples were incubated at ambient temperature for 3.5 h, without shaking, transferred to a 96-well Multiscreen HTS Hi Flow FB filter plate, and filtered with a vacuum manifold (Millipore Corporation, Bedford, MA, USA). Filters were rapidly washed with 3×200µL of PBS at room temperature and dried on the manifold, after which 50 µL of MicroScint 20 scintillation fluid (PerkinElmer, Waltham, MA, USA) were added to each well. After 24 h incubation on an orbital shaker, [ 3 H]PIB binding was quantified in a TopCount scintillation counter (PerkinElmer).
Aβ and Lipid Preparation
Multilamellar vesicles (MLVs) for NMR experiments were prepared by individually dissolving 3.5 mg of [1-13 C]L34[ 15 N]V36 Aβ 42 to 2 mg/mL in HFIP and 17.25 mg of Brain Total Lipid Extract (Avanti Polar Lipids, Alabaster, AL) in chloroform and methanol (9 : 1), then combining to evaporate to a film under vacuum. The film was placed under high vacuum overnight to remove any residual solvent before being suspended in 21 µL 50 mM sodium phosphate buffer (pH 7.2) and 2.6 mL 18 MΩ water and homogenized with three freeze-thaw cycles between liquid N 2 and a 40°C water bath. The sample was then lyophilized and packed into the NMR rotor under positive pressure argon gas.
Solid-state NMR
NMR sample (20 mg) was packed into a 4 mm solid-state NMR rotor and centered using boron nitride spacers. NMR spectra were collected with a Bruker (Billerica, MA) Avance 600 spectrometer using a 4mm HCN BioSolids magic-angle spinning (MAS) probe. MAS frequency was actively controlled at 10,000 ± 2 Hz with cooling and spinning air exit temperature maintained below −1 °C to ensure that MAS and radio-frequency (RF) heating did not denature the samples. 13 C (150.8 MHz) CP-MAS spectra before and after REDOR experiments confirmed that the samples did not change during the experiment. The pulse sequence for 13 C{ 15 N} rotational-echo double-resonance (REDOR) 86 consists of two parts, an S sequence with both 13 C and 15 N pulses, and the S 0 sequence, which is identical but does not contain any 15 N dephasing pulses. Applying pulses to the dephasing 15 N spins interferes with the averaging due to magic-angle spinning, and reintroduces the dipolar coupling that is observed in the REDOR S spectrum, where the signal decays according to both T 2 (spin-spin relaxation) and the heteronuclear 13 C-15 N dipolar coupling. Maximum dephasing occurs when the spacing between π-pulses is equal to ½ of the rotor cycle. The sequence without any 15 N dephasing π-pulses gives the REDOR full-echo or S 0 spectra, where the magnetization decays according to only T 2 . The difference between the REDOR S and S 0 signal (ΔS) is directly proportional to the dipolar coupling, hence the distance between the two spins. xy8 13 C{ 15 N}-REDOR pulse sequence 113 with the dephasing 15 N pulses centered at Tr/2 and refocusing pulses centered at Tr with EXORCYCLE phase cycling 114 of the final Hahnecho 4 µs 13 C (150.8 MHz) π pulse was used. To compensate for pulse imperfections, both the 4 µs 13 C and 8 µs 15 N REDOR rotor synchronized dephasing π pulses were xy8 phasecycled 86 . The initial 1 H 90° pulse was 1.9 µs, 1 H CP RF fields were ramped from 50 to 70 kHz and the 13 C CP RF field was kept constant at 50 kHz. 128 kHz Spinal64 115 1 H (600.3 MHz) decoupling was applied during REDOR evolution and acquisition. SPINAL64 pulse widths and 1 H decoupling resonance frequency were optimized by comparing the peak heights of the CH and CH 2 resonances of fumaric acid monoethyl ester.
REDOR data points are the integrated sum of center-and sideband peaks. Error bars were calculated using the noise of each spectrum as the maximum peak height deviation. To normalize for the decay due to T 2 , individual REDOR curves are plotted as ΔS/S 0 . The ideal scaling factor was determined with 13 C{ 15 N}REDOR spectra of [1-13 C, 15 N]alanine diluted 10:1 with natural abundance alanine. This dilution ratio does not create a perfectly isolated spin-pair due to the probability of having an enriched 13 C/ 15 N alanine as a next nearest neighbor. 105 Correcting for this, the probe REDOR scaling factor was determined to be 93%.
Transmission Electron Microscopy Imaging
After addition to TEM grids, the amyloid peptide assemblies were allowed to adsorb for 1 min before excess peptide solution was wicked away with filter paper. Freshly prepared 2wt % uranyl acetate solutions were added to TEM grids and incubated for 1-2 minutes before wicking and then placed in a vacuum desiccator overnight. TEM micrographs were recorded with a Philips 410 TEM at magnifications ranging from 7100× to 69 000× with a Tungsten filament at an accelerating voltage of 80 kV. Negatives were scanned at 2000 dpi resolution on an Agfa DuoScan flatbed scanner (Agfa Corp., Ridgefield Park, NJ). All staining solutions were prepared fresh and filtered prior to staining to minimize distinguishable artifacts. N-acetyl Aβ (16) (17) (18) (19) (20) (21) (22) peptide bilayer of anti-parallel β-sheets places lysine residues (colored blue) at both ends of each leaflet with TFA ions trapped within the peptide bilayer interface. Expansion shows 6 laminated β-sheets, viewed down the H-bonding axis, with alaninevaline cross-strand pairing within each β-sheet. Peptide is drawn as sticks with lysines colored blue and the remaining amino acids colored grey or white to highlight the two leaflets. TFA anions are shown as spheres with green fluorines, gray carbons and red oxygens. 
